Navigation Links
Kensey Nash Announces $30 Million Share Buyback

EXTON, Pa., Feb. 9 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) today announced that its board of directors has approved a new stock repurchase program.  The new program allows the Company to repurchase an additional $30 million of its issued and outstanding shares of Common Stock, in addition to approximately $3 million currently remaining under the previously announced repurchase program, and has no scheduled expiration.  The Company intends to finance the repurchases using its available cash and liquid investments.

Kensey Nash Corporation plans to repurchase its shares for cash, from time to time in the open market, through block trades or otherwise.  The repurchase program does not require the Company to purchase any specific dollar value or number of shares.  Any purchases under the program will depend on market conditions and may be commenced or suspended at any time or from time to time without prior notice.  As of January 31, 2010, the Company had approximately 10,935,576 shares of Common Stock outstanding.

About Kensey Nash Corporation. Kensey Nash Corporation is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology.  The Company is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials. The Company has an extensive range of products, which are sold through strategic partners in multiple medical markets, including, the cardiology, orthopedic, sports medicine, spine, endovascular and general surgery markets.

Cautionary Note for Forward-Looking Statements.  This press release as well as other Company press releases contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities. The Company has tried to identify these forward looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "would," "forecast," "believe," "guidance," "projection" or similar expressions, but these words are not the exclusive means for identifying such statements.  The Company cautions that a number of risks, uncertainties and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, current economic conditions, foreign currency fluctuations, risks associated with the Company's continued research and development efforts with respect to the endovascular products (including the risk that those efforts will not be successful and that some of the associated milestone payments will not be received), Spectranetics' success in selling the ThromCat™ product, the Company's success in distributing its products into the marketplace, the Company's dependence on three major customers (St. Jude Medical, Arthrex and Orthovita) and their success in selling Kensey Nash related products in the marketplace, the impact of product recalls and other manufacturing issues, the Company's success in its research and development efforts in its cartilage repair and extracellular matrix technologies programs, Synthes' success in selling the Company's extracellular matrix products, the completion of additional clinical trials in both the U.S. and Europe to support regulatory approval of future generations of its products and competition from other technologies.  For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosure under "Risk Factors" in those filings.  Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

SOURCE Kensey Nash Corporation



SOURCE Kensey Nash Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results
2. Kensey Nash Receives FDA 510(k) Clearance for Porcine Dermis Biologic Product
3. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference
4. Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting
5. Kensey Nash Announces IDE Submission for Cartilage Repair Device
6. Portrait Health(TM) Emergency Medical Data Retrieval Program-Glycemion Strategies Announces Free Membership for Diabetes Educators
7. ISTA Pharmaceuticals Announces 2010 Financial Guidance
8. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
9. Hoya Announces Third Quarter Financial Results
10. Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
11. PreXion, Inc. Announces Appointment of Director of Marketing
Post Your Comments:
(Date:10/13/2015)... 13, 2015 According to the ... sponsored by Cardinal Health , achieving both ... diversified pharmacy revenue streams are vital to the ... NCPA Digest affirms that independent community ... in underserved inner city and rural areas," said ...
(Date:10/13/2015)... -- Measurement in accountable care programs is essential for ... gaps in measurement can result in missed opportunities ... new, peer-reviewed study published in The ... measurement gaps for high-priority conditions and identifies ways ... --> "These gaps in measures present ...
(Date:10/13/2015)... DUBLIN , Oct. 13 2015 ... addition of the "US & European markets ... report to their offering. --> ... "US & European markets for Meniscal Repair - ... --> Research and Markets ( ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... According to an article ... has shown that women who successfully lose weight with a bariatric procedure are much ... each year. The article notes that anywhere from 40 to 50 percent of all ...
(Date:10/13/2015)... , ... October 13, 2015 , ... In an age ... costs were 36 percent lower per square foot than in 2009. The Williamsport Regional ... of heating and cooling has decreased by eight percent. , According to Facilities ...
(Date:10/13/2015)... ... October 13, 2015 , ... A child without a healthy mouth is ... the leading remote invisible aligner system, has joined with Global Dental Relief ... For each aligner treatment plan purchased, SmileCareClub will donate one clinic visit to a ...
(Date:10/13/2015)... ... , ... Scientists in Seattle and Vancouver compared the diagnostic value of lung ... Surviving Mesothelioma has just posted an article on the new research. Click here ... the University of British Columbia found that certain genetic alterations were seen just as ...
(Date:10/13/2015)... , ... October 13, 2015 , ... World Patent ... Snow Blanket, a snow melting invention that helps people in clearing snow away from ... will continue to grow at 3.8% per year," says Scott Cooper, CEO and Creative ...
Breaking Medicine News(10 mins):